Publication:
Separate cis-trans Pathways Post-transcriptionally Regulate Murine CD154 (CD40 Ligand) Expression: A NOVEL FUNCTION FOR CA REPEATS IN THE 3′-UNTRANSLATED REGION*

No Thumbnail Available

Date

2008

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

American Society for Biochemistry and Molecular Biology
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Hamilton, B. JoNell, Xiao-Wei Wang, Jane Collins, Donald Bloch, Alan Bergeron, Brian Henry, Benjamin M. Terry, Moe Zan, Andrew J. Mouland, and William F. C. Rigby. 2008. “Separatecis-transPathways Post-Transcriptionally Regulate Murine CD154 (CD40 Ligand) Expression.” Journal of Biological Chemistry 283 (37). American Society for Biochemistry & Molecular Biology (ASBMB): 25606–16. doi:10.1074/jbc.m802492200.

Research Data

Abstract

We report a role for CA repeats in the 3'-untranslated region (3'-UTR) in regulating CD154 expression. Human CD154 is encoded by an unstable mRNA; this instability is conferred in cis by a portion of its 3'-UTR that includes a polypyrimidine-rich region and CA dinucleotide repeat. We demonstrate similar instability activity with the murine CD154 3'-UTR. This instability element mapped solely to a conserved 100-base CU-rich region alone, which we call a CU-rich response element. Surprisingly, the CA dinucleotide-rich region also regulated reporter expression but at the level of translation. This activity was associated with poly(A) tail shortening and regulated by heterogeneous nuclear ribonucleoprotein L levels. We conclude that the CD154 3'-UTR contains dual cis-acting elements, one of which defines a novel function for exonic CA dinucleotide repeats. These findings suggest a mechanism for the association of 3'-UTR CA-rich response element polymorphisms with CD154 overexpression and the subsequent risk of autoimmune disease.

Description

Other Available Sources

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories